Table 2.
Open in new tab

Multivariable logistic regression model of predictors for composite clinical success and in-hospital mortality

OutcomePredictorAdjusted OR95% CI
Composite clinical success
 APACHE II score0.950.92–0.98
 CCI score0.940.85–1.04
 Immunocompromiseda0.680.31–1.46
 Concurrent GN therapy0.320.16–0.63
 Suboptimal C/T doseb0.860.47–1.58
In-hospital mortality
 APACHE II score1.121.07–1.17
 CCI score1.181.03–1.35
 Immunocompromiseda2.981.12–7.87
 Time to C/T therapy1.081.01–1.17
OutcomePredictorAdjusted OR95% CI
Composite clinical success
 APACHE II score0.950.92–0.98
 CCI score0.940.85–1.04
 Immunocompromiseda0.680.31–1.46
 Concurrent GN therapy0.320.16–0.63
 Suboptimal C/T doseb0.860.47–1.58
In-hospital mortality
 APACHE II score1.121.07–1.17
 CCI score1.181.03–1.35
 Immunocompromiseda2.981.12–7.87
 Time to C/T therapy1.081.01–1.17

Bolded numbers are significant with P < 0.05.

APACHE II, Acute Physiology and Chronic Health Evaluation II; C/T, ceftolozane/tazobactam; GN, Gram negative.

a

HIV, prednisone ≥15 mg/day (or equivalent), cancer chemotherapy in preceding 6 months, history of solid organ transplant.

b

Optimal dose: 3 g every 8 h for respiratory infections and 1.5 g every 8 h for all other infections, adjusted for renal function.

Table 2.
Open in new tab

Multivariable logistic regression model of predictors for composite clinical success and in-hospital mortality

OutcomePredictorAdjusted OR95% CI
Composite clinical success
 APACHE II score0.950.92–0.98
 CCI score0.940.85–1.04
 Immunocompromiseda0.680.31–1.46
 Concurrent GN therapy0.320.16–0.63
 Suboptimal C/T doseb0.860.47–1.58
In-hospital mortality
 APACHE II score1.121.07–1.17
 CCI score1.181.03–1.35
 Immunocompromiseda2.981.12–7.87
 Time to C/T therapy1.081.01–1.17
OutcomePredictorAdjusted OR95% CI
Composite clinical success
 APACHE II score0.950.92–0.98
 CCI score0.940.85–1.04
 Immunocompromiseda0.680.31–1.46
 Concurrent GN therapy0.320.16–0.63
 Suboptimal C/T doseb0.860.47–1.58
In-hospital mortality
 APACHE II score1.121.07–1.17
 CCI score1.181.03–1.35
 Immunocompromiseda2.981.12–7.87
 Time to C/T therapy1.081.01–1.17

Bolded numbers are significant with P < 0.05.

APACHE II, Acute Physiology and Chronic Health Evaluation II; C/T, ceftolozane/tazobactam; GN, Gram negative.

a

HIV, prednisone ≥15 mg/day (or equivalent), cancer chemotherapy in preceding 6 months, history of solid organ transplant.

b

Optimal dose: 3 g every 8 h for respiratory infections and 1.5 g every 8 h for all other infections, adjusted for renal function.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close